DOSE INTENSITY ANALYSIS OF CHEMOTHERAPY REGIMENS IN OVARIAN-CARCINOMA
DOSE INTENSITY ANALYSIS OF CHEMOTHERAPY REGIMENS IN OVARIAN-CARCINOMA
复制标题
DOI：
10.1200/jco.1987.5.5.756
复制
发表时间：
1987-05-01
影响因子：
45.3
通讯作者：
HRYNIUK, WM
中科院分区：
文献类型：
--
作者：
LEVIN, L;HRYNIUK, WM
使用特定的 CHAP（环磷酰胺、六甲基三聚氰胺、阿霉素 [Adria Laboratories，哥伦布，俄亥俄州]、顺铂）方案作为标准，分析晚期卵巢癌一线化疗的结果和剂量强度之间的关系。先前描述的技术用于计算包含一种、两种、三种或全部四种 CHAP 药物的治疗方案相对于标准的平均剂量强度。平均相对剂量强度，尤其是顺铂的相对剂量强度，与整个组（不仅仅是缓解者）的临床反应和中位生存时间（MST）显着相关。与单一烷化剂相比，多药物治疗方案具有明显的优势，尤其是含有顺铂的多药物治疗方案。生存率与（多药治疗方案）的缓解率相关。该分析表明剂量强度是治疗结果的决定因素。需要前瞻性随机试验来测试剂量强度是否以及在多大程度上独立于给药总量、体能状态或其他因素来决定结果。如果剂量强度确实决定了结果，则应测试增加剂量强度的方法，以试图改善治疗结果。
The relationship between outcome and dose intensity was analyzed for first-line chemotherapy of advanced ovarian cancer using a particular CHAP (cyclophosphamide, hexamethylmelamine, Adriamycin [Adria Laboratories, Columbus, OH], cisplatin) regimen as the standard. Previously described techniques were used to calculate the average dose intensity of regimens containing one, two, three, or all four drugs of CHAP, relative to the standard. The average relative dose intensity, especially the relative dose intensity of cisplatin, correlated significantly with clinical response and with median survival time (MST) of the entire group (not just the remitters). There was a distinct advantage for multiagent regimens over single alkylating agents and especially for multiagent regimens containing cisplatin. Survival correlated with response rate (of multiagent regimens). This analysis suggests that dose intensity is a determinant of treatment outcome. Prospective randomized trials would be required to test whether, and to what extent, dose intensity determines outcome independently of total amount of drug given, performance status, or other factors. If dose intensity does determine outcome, methods of increasing it should be tested in an attempt to improve treatment results.